Request Trial
18 July 2025VideosAmericasJohn Rearick, Dechert | Michael Penn, BlueRock Therapeutics | Mark Stewart, Merck | Paul Fleming, Seaport Therapeutics | Robin Weatherhead, Ventus Therapeutics

WATCH: Enabling success—mastering s112 in the new era of life sciences patents

Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life sciences patents, as discussed at LSPN.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026   After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.
Americas
CRISPR priority feud ends at USPTO as board reaches decision
30 March 2026   A long-running patent clash over gene editing returns to a fundamental question, as a US court takes another look at the evidence.
Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026   Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.


Editor's picks

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

Editor's picks

Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026
Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
LSPN Awards 2026 finalists revealed
2 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026

More features

UPC refuses early knockout in Illumina–Element dispute
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
CRISPR priority feud ends at USPTO as board reaches decision
Novartis bets $2bn on biologics as Xolair patents fade
WIPR debuts Global In-House Elite 2026
mRNA litigation: Who’s winning, who’s filing, and what’s next
EPO reports record patent filings, but pharma and biotech lag
Masimo convinces judge that Apple took secrets—but it’s not enough